Mendus AB (STU:1YG0) showcases positive trial data and strategic financial moves, despite facing ongoing financial hurdles and market uncertainties.

Sales growth driven by continued strong performance from priority brands including Kisqali (+57% cc), Kesimpta (+36% cc), Pluvicto (+42% cc), Scemblix (+85% cc) and Cosentyx (+8% cc) Operating income ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance ...

Strategic entry into the Norwegian Continental Shelf (NCS) floater market via the Noble Great White reactivation, targeting a capital recovery within the first two years of its three-year contract.

Novartis’ fourth-quarter performance saw net sales decline 1% at constant currencies to $13.3 billion, a reflection of the accelerating impact of U.S. competition and revenue deduction adjustments, ...

Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...

Roman Reigns, a wrestling icon, has a storied career marked by championships and a powerful persona. He emerged from a ...

The plan is to send four elite squad members, three women golfers and three junior golfers, along with a team manager,” ...

AllianceBernstein Holding L.P. (NYSE:AB) Q4 2025 Earnings Call Transcript February 5, 2026 AllianceBernstein Holding L.P.

The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...